Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Pliant Therapeutics, Inc.
Instituto do Cancer do Estado de São Paulo
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Alentis Therapeutics AG
Hoffmann-La Roche
Myeloid Therapeutics
Jonsson Comprehensive Cancer Center
Apollo Therapeutics Ltd
University of Pittsburgh
RenJi Hospital
West China Hospital
Actym Therapeutics, Inc.
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Toray Industries, Inc
Telix Pharmaceuticals (Innovations) Pty Limited
NextPoint Therapeutics, Inc.
Celldex Therapeutics
TransThera Sciences (Nanjing), Inc.
Kinnate Biopharma
Elevation Oncology
SOLTI Breast Cancer Research Group
Rain Oncology Inc
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
TransThera Sciences (Nanjing), Inc.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Jules Bordet Institute
NextCure, Inc.
Universitair Ziekenhuis Brussel
Celon Pharma SA
University of Florida
Hoffmann-La Roche
Klus Pharma Inc.
Tempest Therapeutics
Celldex Therapeutics
Xencor, Inc.
Beijing InnoCare Pharma Tech Co., Ltd.
Quadriga Biosciences, Inc.
Xencor, Inc.
Taizhou EOC Pharma Co., Ltd.
Hoffmann-La Roche
Second Affiliated Hospital, School of Medicine, Zhejiang University
BIND Therapeutics